SciSparc EBITDA 2017-2024 | SPRC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

SciSparc ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

SciSparc ebitda from 2017 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$82.2B
Zoetis (ZTS)	$67.6B
Daiichi Sankyo, - (DSNKY)	$46.9B
Takeda Pharmaceutical (TAK)	$45.4B
BeOne Medicines - (ONC)	$33.4B
Sandoz Group AG (SDZNY)	$25.2B
Summit Therapeutics (SMMT)	$21.8B
Merck (MKKGY)	$16.3B
Shionogi (SGIOY)	$14.7B
United Therapeutics (UTHR)	$13.2B
Neurocrine Biosciences (NBIX)	$12.7B
Orion OYJ (ORINY)	$11.7B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.7B
Corcept Therapeutics (CORT)	$7.6B
Grifols, S.A (GRFS)	$7.4B
Madrigal Pharmaceuticals (MDGL)	$6.9B
Ionis Pharmaceuticals (IONS)	$6.9B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.2B
Hypermarcas (HYPMY)	$2.8B
Catalyst Pharmaceuticals (CPRX)	$2.7B
Crinetics Pharmaceuticals (CRNX)	$2.6B
Procaps Group, S.A (PROCF)	$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.4B
Centessa Pharmaceuticals (CNTA)	$2.1B
Ocular Therapeutix (OCUL)	$2B
BioCryst Pharmaceuticals (BCRX)	$1.8B